Eric Shiozaki brings an uncommon combination of scientific training as a structural biologist with a PhD in Molecular Biology from Princeton and extensive cross-stage healthcare investing experience spanning early-stage biotech venture, late-stage private, public equities, and secondaries across firms like Novo Ventures, DCVC Bio, and now Revelation Partners. His rare trajectory from lab scientist to investor across multiple investment strategies gives him a uniquely panoramic view of capital formation and liquidity paths in healthcare, particularly in biopharma and medical devices where his deep domain expertise stands out within the secondaries platform.